How Fast People With Pulmonary Fibrosis Can Breathe In Through Inhaler Devices
Measures breathing-in speed through simulated inhaler resistance in people with pulmonary fibrosis.
Plain-language title generated from the registry record
Registry title: Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07820254, who can take part
Where in China
- Shanghai Pulmonary HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Pulmonary Hospital, Shanghai, China
- Trial code
- NCT07820254
- Record updated
- 15 September 2026
- Original description
The goal of this observational study is to learn about the inspiratory flow rate capability in patients with pulmonary fibrosis (IPF or PPF) when using inhaler devices with different resistances. The main questions it aims to answer are:Read full original descriptionShow less
A Clinical Study on Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
The goal of this observational study is to learn about the inspiratory flow rate capability in patients with pulmonary fibrosis (IPF or PPF) when using inhaler devices with different resistances. The main questions it aims to answer are:
What is the peak inspiratory flow rate (PIFR) that patients with pulmonary fibrosis can achieve through a medium-resistance inhaler device?
What is the peak inspiratory flow rate (PIFR) that patients with pulmonary fibrosis can achieve through a high-resistance inhaler device?
What is the inspiratory time (EIT) for each resistance level?
Participants will use a portable device called In-Check™ DIAL G16, which simulates the resistance of different dry powder inhalers. Each participant will perform two breathing tests at a medium-resistance setting and two breathing tests at a high-resistance setting, with a 2-minute rest between settings. The device measures how fast air is breathed in and how long each breath lasts.
This study will enroll 60 patients diagnosed with IPF or PPF at Shanghai Pulmonary Hospital. Participants will be involved for approximately 30 to 60 minutes, including training on how to use the device and the breathing tests. The study involves no drugs or invasive procedures.
Inclusion: Age 18-80 years (inclusive), either sex; Diagnosis of pulmonary fibrosis (IPF or PPF) according to the ATS/ERS/JRS/ALAT 2022 guidelines (with traceable diagnostic evidence such as medical records, confirmed by a radiologist); Forced vital capacity (FVC) ≥ 45% of predicted normal value within 2 months before screening; Diffusing capacity for carbon monoxide (DLCO) > 25% of predicted normal value within 2 months before screening; Voluntary participation with written informed consent.
Exclusion: Patients with impaired consciousness, dementia, or various psychiatric disorders; Patients with major diseases or conditions other than the IPF under study that, in the investigator's judgment, may put the patient at risk by participating in the trial; Patients unable to operate the inspiratory flow measurement device as instructed by the investigator; Any participant deemed unsuitable for enrollment by the investigator.